89 related articles for article (PubMed ID: 15238567)
1. Trial of preventing hypertension: design and 2-year progress report.
Julius S; Nesbitt S; Egan B; Kaciroti N; Schork MA; Grozinski M; Michelson E;
Hypertension; 2004 Aug; 44(2):146-51. PubMed ID: 15238567
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
3. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
[TBL] [Abstract][Full Text] [Related]
4. [Prevension of hypertension by angiotensin receptor blockers in human--TROPHY study].
Ohya Y; Inoue T
Nihon Rinsho; 2008 Aug; 66(8):1596-600. PubMed ID: 18700563
[TBL] [Abstract][Full Text] [Related]
5. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
Hoy SM; Keating GM
Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
[TBL] [Abstract][Full Text] [Related]
6. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
[TBL] [Abstract][Full Text] [Related]
7. In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension.
Julius S; Egan BM; Kaciroti NA; Nesbitt SD; Chen AK;
J Hypertens; 2014 Feb; 32(2):251-9. PubMed ID: 24275841
[TBL] [Abstract][Full Text] [Related]
8. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
Wei F; Jia XJ; Yu SQ; Gu Y; Wang L; Guo XM; Wang M; Zhu F; Cheng X; Wei YM; Zhou ZH; Fu M; Liao YH;
Heart; 2011 Mar; 97(6):479-84. PubMed ID: 21296780
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation.
Radke PW; Figulla HR; Drexler H; Klues HG; Mügge A; Silber S; Daniel W; Schmeisser A; Reifart N; Motz W; Büttner HJ; Fischer D; Ortlepp JR; Schaefers K; Hoffmann R; Hanrath P;
Am Heart J; 2006 Oct; 152(4):761.e1-6. PubMed ID: 16996855
[TBL] [Abstract][Full Text] [Related]
10. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
11. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
McInnes GT; O'Kane KP; Jonker J; Roth J
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
[TBL] [Abstract][Full Text] [Related]
13. Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY study.
Nesbitt SD; Julius S; Leonard D; Egan BM; Grozinski M;
Am J Hypertens; 2005 Jul; 18(7):980-5. PubMed ID: 16053996
[TBL] [Abstract][Full Text] [Related]
14. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
Sjølie AK; Klein R; Porta M; Orchard T; Fuller J; Parving HH; Bilous R; Chaturvedi N;
Lancet; 2008 Oct; 372(9647):1385-93. PubMed ID: 18823658
[TBL] [Abstract][Full Text] [Related]
15. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
London G; Schmieder R; Calvo C; Asmar R
Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
[TBL] [Abstract][Full Text] [Related]
16. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
[TBL] [Abstract][Full Text] [Related]
17. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
Chaturvedi N; Porta M; Klein R; Orchard T; Fuller J; Parving HH; Bilous R; Sjølie AK;
Lancet; 2008 Oct; 372(9647):1394-402. PubMed ID: 18823656
[TBL] [Abstract][Full Text] [Related]
18. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of high-normal blood pressure with angiotensin receptor blockers. TROPHY Study (Trial of Preventing Hypertension)].
Mann J
Internist (Berl); 2007 Apr; 48(4):436-8. PubMed ID: 17342351
[No Abstract] [Full Text] [Related]
20. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
